Private Equity And VC Fund Data: What Do The Numbers Show?

In Vivo examines trends in the venture capital and private equity funding landscapes for biotech and pharma – looking at both expenditure and gathering of capital resources.

2021 was a landmark year for private capital fundraising across many sectors with the excitable market allowing for plentiful, early exits. The biopharma industry saw particular interest as the COVID-19 pandemic drew attention to potential gains to be made from the sector. Has the appetite for investing in drug development waivered now the pandemic has subsided? 

Fundraising for biopharma VC looks to have normalized to pre-2018 levels after the giddy heights of 2021, according to In...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deal-Making

Deals In Depth: July 2025

 
• By 

Six $1bn+ alliances were penned in July, and two exceeded $2bn.

Deals Shaping The Industry, July 2025

An interactive look at pharma, medtech and diagnostics deals made during July 2025. Data courtesy of Biomedtracker.

Dealmaking Quarterly Statistics, Q2 2025

 
• By 

During Q2, biopharma merger and acquisition deal value reached $24.6bn and drew in $60.7bn in potential deal value from alliances. Device company M&A values reached $223m, while in vitro diagnostics and research tools players’ M&A activity totaled $802m.

Financing Quarterly Statistics, Q2 2025

 
• By 

During Q2, biopharmas brought in an aggregate $17.5bn in financing and device company fundraising totaled $2.7bn; while in vitro diagnostic firms and research tools players raised $1.7bn

More from In Vivo

Podcast: Tevard CEO Sees Hope For His Daughter In Company’s tRNA Platform

 
• By 

Tevard Biosciences CEO Daniel Fischer discusses how engineered suppressor tRNAs overcome nonsense mutations, restoring full-length protein production to treat rare genetic diseases like Dravet syndrome.

Deals In Depth: July 2025

 
• By 

Six $1bn+ alliances were penned in July, and two exceeded $2bn.

Execs On The Move: July 2025

 
• By 

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.